The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2
Authors:
- R C SteinRSR C Stein
- V MalkovskaVMV Malkovska
- S MorganSMS Morgan
- A GalazkaAGA Galazka
- C AniszewskiCAC Aniszewski
- S E RoySRS E Roy
- R J ShearerRSR J Shearer
- R A MarsdenRMR A Marsden
- D BevanDBD Bevan
- E C Gordon-SmithEGE C Gordon-Smith
- 1 February 1991
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 63 (2) , 275-278
Abstract
Thirty-five patients with advanced malignant disease have been treated as outpatients with increasing doses (0.1-100 mcg) of interleukin 2 (IL2) by once daily self-administered subcutaneous (s.c.) injection, 5 days weekly for 8 weeks followed by a 4 week observation period. Systemic side effects were not experienced by patients at the 3 lower doses. Three patients required dose reduction from 100 mcg daily because of intolerance (fever, rash, lethargy, nausea and vomiting) and one patient was discontinued because of dyspnoea. We observed immunological effects at the 100 mcg dose (but not at the lower doses). These consisted of (a) a modest sustained lymphocytosis, (b) eosinophilia in six (out of nine) patients and (c) a significant rise in IL2-stimulated peripheral blood lymphocyte activated killer (LAK) cell activity in six (out of nine) patients to a mean of 2.0 times pretreatment levels (P less than 0.01). Two (out of nine) patients with renal cell carcinoma treated with 100 mcg daily had partial responses of duration 4 and 9 months respectively and a further three had disease stabilisation for at least 3 months. Low dose long-term s.c. IL2 is clinically and immunologically active, and in comparison to other IL2 regimens it has minor toxicity and is easy to administer. These characteristics make low dose s.c. IL2 suitable for study in the adjuvant setting.Keywords
This publication has 17 references indexed in Scilit:
- Immunologic study of human recombinant interleukin-2 (low dose) in patients with advanced renal cell carcinomaUrology, 1989
- The international standard for human interleukin-2Journal of Immunological Methods, 1988
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Recombinant interleukin-2 directly augments the cytotoxicity of human monocytesNature, 1987
- Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.The Journal of Immunology, 1986
- Characterization of human interleukin 2 derived from Escherichia coliBiochemical Journal, 1985
- Reporting results of cancer treatmentCancer, 1981
- T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for ActivityThe Journal of Immunology, 1978